Irbesartan Pharmakern (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor. By preventing angiotensin II from binding, it stops vasoconstriction and aldosterone release, leading to vessel relaxation, lower blood pressure, and reduced stress on the kidneys.

The appropriate dose of Irbesartan Pharmakern is set by the prescribing clinician based on the individual’s blood pressure, kidney function, and overall health status. Dosage may be adjusted during treatment to achieve target blood‑pressure goals.

Irbesartan is classified as contraindicated during pregnancy because it may cause fetal toxicity. Safety during breastfeeding has not been established, so the drug should be avoided unless the benefits clearly outweigh the risks and a healthcare professional advises otherwise.

To order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, which generally offers similar blood‑pressure reduction to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers or diuretics, ARBs provide a different mechanism focused on the renin‑angiotensin system, making them useful in patients who need renal protection.

Irbesartan Pharmakern tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability.

Irbesartan Pharmakern is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events include angioedema (swelling of the face, lips, tongue), severe hyperkalemia (high potassium levels), and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden weakness, or a marked change in urine output.

Irbesartan should not be used by individuals with known hypersensitivity to irbesartan or any ARB, pregnant women, or patients with severe hepatic impairment. Caution is also advised for those with bilateral renal artery stenosis or uncontrolled hyperkalemia.